{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:15:38Z","timestamp":1760242538974},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:p>The role of isocitrate dehydrogenase mutations as a therapeutic target for cancer therapy is examined.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0429","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T05:56:04Z","timestamp":1326261364000},"page":"5-8","source":"Crossref","is-referenced-by-count":17,"title":["Cancer-Associated Isocitrate Dehydrogenase Mutations"],"prefix":"10.1093","volume":"17","author":[{"given":"Katharine E.","family":"Yen","sequence":"first","affiliation":[{"name":"Agios Pharmaceuticals, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Schenkein","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"2021122307521580700_B1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"2021122307521580700_B2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122307521580700_B3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"2021122307521580700_B4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of IDH1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"The Oncologist"},{"key":"2021122307521580700_B5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"2021122307521580700_B6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021122307521580700_B7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122307521580700_B8","article-title":"Unambiguous detection of 2-hydroxyglutarate in IDH-mutated glioma patients by spectral-editing and 2D correlation magnetic resonance spectroscopy","author":"Andronesi","year":"2011","journal-title":"Sci Transl Med"},{"key":"2021122307521580700_B9","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"2021122307521580700_B10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008","journal-title":"Acta Neuropathol"},{"key":"2021122307521580700_B11","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4161\/cc.8.11.8594","article-title":"Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children","volume":"8","author":"Hayden","year":"2009","journal-title":"Cell Cycle"},{"key":"2021122307521580700_B12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009","journal-title":"Acta Neuropathol"},{"key":"2021122307521580700_B13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122307521580700_B14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122307521580700_B15","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation","volume":"115","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"2021122307521580700_B16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"key":"2021122307521580700_B17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122307521580700_B18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"key":"2021122307521580700_B19","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122307521580700_B20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/leu.2010.56","article-title":"Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study","volume":"24","author":"Ho","year":"2010","journal-title":"Leukemia"},{"key":"2021122307521580700_B21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.24379","article-title":"Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers","volume":"125","author":"Kang","year":"2009","journal-title":"Int J Cancer"},{"key":"2021122307521580700_B22","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1210\/jc.2009-2170","article-title":"Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas","volume":"95","author":"Gaal","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122307521580700_B23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sjoblom","year":"2006","journal-title":"Science"},{"key":"2021122307521580700_B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.20937","article-title":"IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors","volume":"30","author":"Bleeker","year":"2009","journal-title":"Hum Mutat"},{"key":"2021122307521580700_B25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbrc.2010.02.095","article-title":"Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer","volume":"393","author":"Murugan","year":"2010","journal-title":"Biochem Biophys Res Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2011-0429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0429","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/1\/5\/41859571\/oncolo_17_1_5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/1\/5\/41859571\/oncolo_17_1_5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T18:41:02Z","timestamp":1640284862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/1\/5\/6403188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,10]]},"published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0429","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,1,1]]},"published":{"date-parts":[[2012,1,1]]}}}